Changing the course of cancer treatment

We explore the power of the immune system to improve long-term survival of cancer patients, while preserving health and quality of life.
About us
Latest news

Mendus to present multiple abstracts at ASH 2024, including survival update of ADVANCE II trial with lead program vididencel in AML

Learn more
<p>Surfer woman running with surfboard in Lanzarote Canary Islands, Famara beach</p>

Gaining the
upper hand

Today, tumor recurrence is the main cause of cancer-related deaths. We aim to reduce tumor recurrence by harnessing the immune system to act against residual cancer cells.

What we do
<p>Two chemistry laboratory researchers, a young man and a young woman working together in a biology, chemistry research laboratory.= in a university. Focus on the laboratory equipment with the personnel in the background. Photographed in horizontal format.</p>

New ways to make a difference

We apply our understanding of dendritic cell biology to design cancer immunotherapies that stimulate active immunity, the only long-lasting form of immunity.

About us
<p>Molecular Structure. Science background. 3D Render</p>

Invest in future cancer care

Mendus is listed on NASDAQ Stockholm under the ticker symbol IMMU. You will find all relevant information on the Mendus share in our Investors section.

Investors

Latest news

News and Events
No articles found

A life-changing career

At Mendus, we share a strong commitment to improve the lives of people with cancer. And we do it as a team who values honesty and togetherness. Join us and help change cancer treatment at its core.

Careers